Top

European Journal of Medical Research

Published in:

Open Access 01-12-2024 | Adrenocortical Carcinoma | Research

Human pan-cancer analysis of the predictive biomarker for the CDKN3

Authors: Yingjun Chen, Dai Li, Kaihui Sha, Xuezhong Zhang, Tonggang Liu

Published in: European Journal of Medical Research | Issue 1/2024

Abstract

Background

Cell cycle protein-dependent kinase inhibitor protein 3 (CDKN3), as a member of the protein kinase family, has been demonstrated to exhibit oncogenic properties in several tumors. However, there are no pan-carcinogenic analyses for CDKN3.

Methods

Using bioinformatics tools such as The Cancer Genome Atlas (TCGA) and the UCSC Xena database, a comprehensive pan-cancer analysis of CDKN3 was conducted. The inverstigation encompassed the examination of CDKN3 function actoss 33 different kinds of tumors, as well as the exploration of gene expressions, survival prognosis status, clinical significance, DNA methylation, immune infiltration, and associated signal pathways.

Results

CDKN3 was significantly upregulated in most of tumors and correlated with overall survival (OS) of patients. Methylation levels of CDKN3 differed significantly between tumors and normal tissues. In addition, infiltration of CD4 + T cells, cancer-associated fibroblasts, macrophages, and endothelial cells were associated with CDKN3 expression in various tumors. Mechanistically, CDKN3 was associated with P53, PI3K-AKT, cell cycle checkpoints, mitotic spindle checkpoint, and chromosome maintenance.

Conclusion

Our pan-cancer analysis conducted in the study provides a comprehensive understanding of the involvement of CDKN3 gene in tumorigenesis. The findings suggest that targeting CDKN3 may potentially lead to novel therapeutic strategies for the treatment of tumors.

Available only for authorised users

Seferbekova Z, Lomakin A, Yates LR, Gerstung M. Spatial biology of cancer evolution. Nat Rev Genet. 2023;24:295–313. https://doi.org/10.1038/s41576-022-00553-x.CrossRefPubMed

Del Giudice M, et al. FOXA1 regulates alternative splicing in prostate cancer. Cell Rep. 2022;40(13): 111404. https://doi.org/10.1016/j.celrep.2022.111404.CrossRefPubMedPubMedCentral

Weeden CE, Hill W, Lim EL, Grönroos E, Swanton C. Impact of risk factors on early cancer evolution. Cell. 2023;186:1541–63. https://doi.org/10.1016/j.cell.2023.03.013.CrossRefPubMed

Wang L, Sun L, Huang J, Jiang M. Cyclin-dependent kinase inhibitor 3 (CDKN3) novel cell cycle computational network between human non-malignancy associated hepatitis/cirrhosis and hepatocellular carcinoma (HCC) transformation. Cell Prolif. 2011;44:291–9. https://doi.org/10.1111/j.1365-2184.2011.00752.x.CrossRefPubMedPubMedCentral

Gyuris J, Golemis E, Chertkov H, Brent R. Cdi1, a human G1 and S phase protein phosphatase that associates with Cdk2. Cell. 1993;75:791–803. https://doi.org/10.1016/0092-8674(93)90498-f.CrossRefPubMed

Hannon GJ, Casso D, Beach D. KAP: a dual specificity phosphatase that interacts with cyclin-dependent kinases. Proc Natl Acad Sci USA. 1994;91:1731–5. https://doi.org/10.1073/pnas.91.5.1731.CrossRefPubMedPubMedCentral

Johnson LN, et al. Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2. Pharmacol Ther. 2002;93:113–24. https://doi.org/10.1016/s0163-7258(02)00181-x.CrossRefPubMed

Morris EJ, et al. E2F1 represses beta-catenin transcription and is antagonized by both pRB and CDK8. Nature. 2008;455:552–6. https://doi.org/10.1038/nature07310.CrossRefPubMedPubMedCentral

Okamoto K, Kitabayashi I, Taya Y. KAP1 dictates p53 response induced by chemotherapeutic agents via Mdm2 interaction. Biochem Biophys Res Commun. 2006;351:216–22. https://doi.org/10.1016/j.bbrc.2006.10.022.CrossRefPubMed

10.

Nordskog BK, Blixt AD, Morgan WT, Fields WR, Hellmann GM. Matrix-degrading and pro-inflammatory changes in human vascular endothelial cells exposed to cigarette smoke condensate. Cardiovasc Toxicol. 2003;3:101–17. https://doi.org/10.1385/ct:3:2:101.CrossRefPubMed

11.

Ou H, et al. Identifying key genes related to inflammasome in severe COVID-19 patients based on a joint model with random forest and artificial neural network. Front Cell Infect Microbiol. 2023;13:1139998. https://doi.org/10.3389/fcimb.2023.1139998.CrossRefPubMedPubMedCentral

12.

Li X, et al. Transcriptomics analysis and benchmark concentration estimating-based in vitro test with IOSE80 cells to unveil the mode of action for female reproductive toxicity of bisphenol A at human-relevant levels. Ecotoxicol Environ Saf. 2022;237: 113523. https://doi.org/10.1016/j.ecoenv.2022.113523.CrossRefPubMed

13.

Zhang M, Wang X, Yao J, Qiu Z. Long non-coding RNA NEAT1 inhibits oxidative stress-induced vascular endothelial cell injury by activating the miR-181d-5p/CDKN3 axis. Artif Cell Nanomed Biotechnol. 2019;47:3129–37. https://doi.org/10.1080/21691401.2019.1646264.CrossRef

14.

Nalepa G, et al. The tumor suppressor CDKN3 controls mitosis. J Cell Biol. 2013;201:997–1012. https://doi.org/10.1083/jcb.201205125.CrossRefPubMedPubMedCentral

15.

Jia Z, et al. KLF7 promotes preadipocyte proliferation via activation of the Akt signaling pathway by Cis-regulating CDKN3. Acta Biochim Biophys Sin. 2022;54:1486–96. https://doi.org/10.3724/abbs.2022144.CrossRefPubMedPubMedCentral

16.

Berumen J, Espinosa AM, Medina I. Targeting CDKN3 in cervical cancer. Expert Opin Ther Targets. 2014;18:1149–62. https://doi.org/10.1517/14728222.2014.941808.CrossRefPubMed

17.

Li T, Xue H, Guo Y, Guo K. CDKN3 is an independent prognostic factor and promotes ovarian carcinoma cell proliferation in ovarian cancer. Oncol Rep. 2014;31:1825–31. https://doi.org/10.3892/or.2014.3045.CrossRefPubMed

18.

Li M, Che N, Jin Y, Li J, Yang W. CDKN3 overcomes bladder cancer cisplatin resistance via LDHA-dependent glycolysis reprogramming. Onco Targets Ther. 2022;15:299–311. https://doi.org/10.2147/ott.S358008.CrossRefPubMedPubMedCentral

19.

Li WH, Zhang L, Wu YH. CDKN3 regulates cisplatin resistance to colorectal cancer through TIPE1. Eur Rev Med Pharmacol Sci. 2020;24:3614–23. https://doi.org/10.26355/eurrev_202004_20823.CrossRefPubMed

20.

Dai W, et al. CDKN3 expression predicates poor prognosis and regulates adriamycin sensitivity in hepatocellular carcinoma in vitro. J Int Med Res. 2020;48:300060520936879. https://doi.org/10.1177/0300060520936879.CrossRefPubMed

21.

Fan C, et al. Overexpression of major CDKN3 transcripts is associated with poor survival in lung adenocarcinoma. Br J Cancer. 2015;113:1735–43. https://doi.org/10.1038/bjc.2015.378.CrossRefPubMedPubMedCentral

22.

Abdel-Tawab MS, et al. Evaluation of gene expression of PLEKHS1, AADAC, and CDKN3 as novel genomic markers in gastric carcinoma. PLoS ONE. 2022;17: e0265184. https://doi.org/10.1371/journal.pone.0265184.CrossRefPubMedPubMedCentral

23.

Qi L, et al. Significant prognostic values of differentially expressed-aberrantly methylated hub genes in breast cancer. J Cancer. 2019;10:6618–34. https://doi.org/10.7150/jca.33433.CrossRefPubMedPubMedCentral

24.

Long J, et al. DNA methylation-driven genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinoma. Theranostics. 2019;9:7251–67. https://doi.org/10.7150/thno.31155.CrossRefPubMedPubMedCentral

25.

Cen J, et al. Circular RNA circSDHC serves as a sponge for miR-127-3p to promote the proliferation and metastasis of renal cell carcinoma via the CDKN3/E2F1 axis. Mol Cancer. 2021;20:19. https://doi.org/10.1186/s12943-021-01314-w.CrossRefPubMedPubMedCentral

26.

Jiang CH, et al. Bioinformatics-based screening of key genes for transformation of liver cirrhosis to hepatocellular carcinoma. J Transl Med. 2020;18:40. https://doi.org/10.1186/s12967-020-02229-8.CrossRefPubMedPubMedCentral

27.

Pabla S, et al. Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients. J Immunother Cancer. 2019;7:27. https://doi.org/10.1186/s40425-019-0506-3.CrossRefPubMedPubMedCentral

28.

Lu S, et al. Comprehensive analysis of the prognosis and immune infiltration landscape of RNA methylation-related subtypes in pancreatic cancer. BMC Cancer. 2022;22:804. https://doi.org/10.1186/s12885-022-09863-z.CrossRefPubMedPubMedCentral

29.

Li A, et al. ZNF677 suppresses renal cell carcinoma progression through N6-methyladenosine and transcriptional repression of CDKN3. Clin Transl Med. 2022;12: e906. https://doi.org/10.1002/ctm2.906.CrossRefPubMedPubMedCentral

30.

Chang SL, et al. CDKN3 expression is an independent prognostic factor and associated with advanced tumor stage in nasopharyngeal carcinoma. Int J Med Sci. 2018;15:992–8. https://doi.org/10.7150/ijms.25065.CrossRefPubMedPubMedCentral

31.

Wang W, et al. An eleven gene molecular signature for extra-capsular spread in oral squamous cell carcinoma serves as a prognosticator of outcome in patients without nodal metastases. Oral Oncol. 2015;51:355–62. https://doi.org/10.1016/j.oraloncology.2014.12.012.CrossRefPubMed

32.

Islam MA, et al. Exploring core genes by comparative transcriptomics analysis for early diagnosis, prognosis, and therapies of colorectal cancer. Cancers. 2023. https://doi.org/10.3390/cancers15051369.CrossRefPubMedPubMedCentral

33.

Niculescu MD, Yamamuro Y, Zeisel SH. Choline availability modulates human neuroblastoma cell proliferation and alters the methylation of the promoter region of the cyclin-dependent kinase inhibitor 3 gene. J Neurochem. 2004;89:1252–9. https://doi.org/10.1111/j.1471-4159.2004.02414.x.CrossRefPubMedPubMedCentral

34.

Liu D, et al. YY1 suppresses proliferation and migration of pancreatic ductal adenocarcinoma by regulating the CDKN3/MdM2/P53/P21 signaling pathway. Int J Cancer. 2018;142:1392–404. https://doi.org/10.1002/ijc.31173.CrossRefPubMed

35.

Gao LM, et al. Tumor-suppressive effects of microRNA-181d-5p on non-small-cell lung cancer through the CDKN3-mediated Akt signaling pathway in vivo and in vitro. Am J Physiol Lung Cell Mol Physiol. 2019;316:L918-933. https://doi.org/10.1152/ajplung.00334.2018.CrossRefPubMed

36.

Ferro M, et al. Radiogenomics in renal cancer management—current evidence and future prospects. Int J Mol Sci. 2023;24(5):4615. https://doi.org/10.3390/ijms24054615.CrossRefPubMedCentral

Title: Human pan-cancer analysis of the predictive biomarker for the CDKN3
Authors: Yingjun Chen
Dai Li
Kaihui Sha
Xuezhong Zhang
Tonggang Liu
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Adrenocortical Carcinoma
Choroidal Melanoma
Mesothelioma
Pancreatic Cancer
Pancreatic Cancer
Published in: European Journal of Medical Research / Issue 1/2024
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/s40001-024-01869-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Human pan-cancer analysis of the predictive biomarker for the CDKN3

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

Development and validation of a nomogram for predicting in-hospital mortality of patients with cervical spine fractures without spinal cord injury

Analysis of related factors for neuropsychiatric comorbidities in children with epilepsy

Paclitaxel and its semi-synthetic derivatives: comprehensive insights into chemical structure, mechanisms of action, and anticancer properties

Optimizing patient outcomes: a comprehensive evaluation of protocolized sedation in intensive care settings: a systematic review and meta-analysis

Investigating the efficacy of vacuum sealing drainage versus traditional negative pressure drainage in treating deep incision infections following posterior cervical internal fixation—a retrospective cohort study

Correction: Exploring the association between triglyceride-glucose index and thyroid function